Literature DB >> 2434191

Monoaminergic innervation of the frontal and temporal lobes in Alzheimer's disease.

A M Palmer, G K Wilcock, M M Esiri, P T Francis, D M Bowen.   

Abstract

Seven markers of ascending (corticopetal) dopaminergic, noradrenergic and serotonergic neurones and choline acetyltransferase activity have been studied postmortem in frontal and temporal cortex from subjects with Alzheimer's disease and compared with a matched group of controls. Dopaminergic neurones (concentrations of dopamine, dihydroxyphenylacetic acid and homovanillic acid) were not deficient but some markers of the other neurones were affected. Noradrenaline and serotonin concentrations were reduced whereas the concentrations of their metabolites were either unaltered (5-hydroxyindoleacetic acid) or increased (3-methoxy-4-hydroxyphenylglycol). All deficits were most pronounced in the temporal cortex. Severely demented subjects had evidence of generalized neuronal loss, whereas those with moderate dementia showed significant loss of only choline acetyltransferase activity. In Alzheimer subjects, a significant relationship (inverse) was found between 5-hydroxyindoleacetic acid concentration and the number of neurofibrillary tangles.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2434191     DOI: 10.1016/0006-8993(87)91408-9

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  29 in total

1.  Effect of aging on lazabemide binding, monoamine oxidase activity and monoamine metabolites in human frontal cortex.

Authors:  M D Galva; G P Bondiolotti; M Olasmaa; G B Picotti
Journal:  J Neural Transm Gen Sect       Date:  1995

Review 2.  Turning on the Light Within: Subcortical Nuclei of the Isodentritic Core and their Role in Alzheimer's Disease Pathogenesis.

Authors:  Panos Theofilas; Sara Dunlop; Helmut Heinsen; Lea Tenenholz Grinberg
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

3.  Sustained attention in mild Alzheimer's disease.

Authors:  Anna Maria Berardi; Raja Parasuraman; James V Haxby
Journal:  Dev Neuropsychol       Date:  2005       Impact factor: 2.253

Review 4.  Activating the damaged basal forebrain cholinergic system: tonic stimulation versus signal amplification.

Authors:  M Sarter; J P Bruno; P Dudchenko
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 5.  The basis for behavioural disturbances in dementia.

Authors:  M M Esiri
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-08       Impact factor: 10.154

6.  A roadmap for investigating the role of the prion protein in depression associated with neurodegenerative disease.

Authors:  Danielle Beckman; Rafael Linden
Journal:  Prion       Date:  2016-03-03       Impact factor: 3.931

7.  Escitalopram Ameliorates Forskolin-Induced Tau Hyperphosphorylation in HEK239/tau441 Cells.

Authors:  Qing-Guo Ren; Yan-Juan Wang; Wei-Gang Gong; Qi-Da Zhou; Lin Xu; Zhi-Jun Zhang
Journal:  J Mol Neurosci       Date:  2015-02-17       Impact factor: 3.444

Review 8.  Serotonergic therapies for cognitive symptoms in Alzheimer's disease: rationale and current status.

Authors:  Maria J Ramirez; Mitchell K P Lai; Rosa M Tordera; Paul T Francis
Journal:  Drugs       Date:  2014-05       Impact factor: 9.546

9.  Therapeutic effect of THA on hemicholinium-3-induced learning impairment is independent of serotonergic and noradrenergic systems.

Authors:  J J Hagan; J H Jansen; F E Nefkens; T de Boer
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 10.  Monoamine neurons in aging and Alzheimer's disease.

Authors:  A M Palmer; S T DeKosky
Journal:  J Neural Transm Gen Sect       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.